Author

A. Mangoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. M. Ashley· 2 shared A. Briley· 1 shared B. E. Foreman· 1 shared B. T. Whitfield· 1 shared C. E. Stewart· 1 shared C. Fraley· 1 shared C. J. Pirozzi· 1 shared D. G. Kirsch· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. M. Ashley

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ataxia-telangiectasia mutated (Atm) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy

A. Mangoli, S. Wu, H. Q. Liu, M. Aksu, V. J. Jain, B. E. Foreman, J. A. Regal, L. B. Weidenhammer, C. E. Stewart, M. E. Guerra Garcia, E. Hocke, K. Abramson, N. T. Williams, L. Luo, K. Deland, , Z. J. Reitman

This study shows that disrupting ATM enhances radiation therapy efficacy in p53-mutant DMGs but not p53-wildtype DMGs using mouse models.

bioRxiv · Oct 18, 2023Cancer Biology

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

S. Hariharan, B. T. Whitfield, C. J. Pirozzi, M. S. Waitkus, M. C. Brown, M. L. Bowie, D. M. Irvin, K. Roso, R. Fuller, J. Hostettler, S. Dharmaiah, E. A. Gibson, A. Briley, A. Mangoli, C. Fraley, , D. M. Ashley

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

bioRxiv · Apr 20, 2023 · PreprintCancer Biology